TIRZEPATIDE

Tirzepatide is a dual incretin mimetic investigated for its concomitant agonism at GIPR (glucose-dependent insulinotropic polypeptide receptor) and GLP-1R (glucagon-like peptide-1 receptor). In research settings, tirzepatide is used to explore combinatorial incretin biology, including effects on glycemic control mechanisms, energy balance, and weight-regulatory neuroendocrine pathways, with attention to β-cell function and gut–brain metabolic signaling.

Targets: GIPR and GLP-1R on pancreatic islets and central/peripheral metabolic circuits.
Mode: Biased, long-acting incretin receptor agonism → augmentation of glucose-dependent insulin secretion, attenuation of inappropriate glucagon release, delayed gastric emptying, and modulation of hypothalamic satiety signaling.
Pathways: cAMP/PKA and PI3K/Akt axes → transcriptional programs governing nutrient handling, insulinotropic responsiveness, and appetite-regulatory neurocircuitry in preclinical and translational models.

Dual-incretin synergy mapping • β-cell stimulus–secretion coupling • Hepatic and adipose insulin sensitivity • Appetite and reward-circuit modulation • Energy expenditure and substrate utilization • Comparative incretin pharmacology versus selective GLP-1R agonists.

Revitalized Health peptides are produced under cGMP-aligned conditions using pharmaceutical-grade inputs. Each tirzepatide lot is confirmed at ≥99% purity by HPLC with structure/identity verified via LC-MS/MS. Lots undergo appearance and solubility checks, and microbial/endotoxin screening to research-grade specifications. Batch-specific Certificates of Analysis documenting methods and results are available.

Store lyophilized vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide integrity and receptor-binding fidelity.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic use. Supplied exclusively to qualified professionals conducting controlled scientific studies.

Identity: Tirzepatide, a long-acting peptide co-agonist at GIP and GLP-1 receptors with albumin-affinity design for once-weekly dosing.
Mode: Co-activation of GIPR and GLP-1R enhances glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and lowers appetite/energy intake; downstream effects include improved glycemia and weight metrics in large RCTs.
Analytics: Identity/purity by HPLC/LC-MS; peptide content & counter-ion; stability (accelerated/real-time). PD readouts: fasting/post-prandial glucose, HbA1c, OGTT, body weight/composition (DXA), gastric emptying tests, indirect calorimetry. Monitoring (class): GI tolerability (nausea/vomiting), heart-rate change, gallbladder events; pancreatitis symptoms; thyroid C-cell signal considerations based on GLP-1 RA class context. Marketing pages should avoid disease-treatment claims.